Efficient and non-invasive platform for the diagnosis and subtyping of X-linked Alport syndrome leveraging interfacial synergistic engineered MXene@AuNWs
Frontiers in Bioengineering and Biotechnology · 20.11.2026 · 14
DOI: 10.3389/fbioe.2026.1958798 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 20.11.2026. Verfasst von Mengying Li und 6 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Development Foundation.
Abstract (Originalsprache)
Introduction
X-linked Alport syndrome (XLAS) is a hereditary nephropathy caused primarily by mutations in the COL4A5 gene and is characterized by progressive nephritis, hearing loss, and ocular abnormalities. Early diagnosis and the identification of specific biomarkers are critical for the effective management of XLAS.
Methods
We developed a laser desorption/ionization mass spectrometry (LDI-MS) metabolomics approach based on a gold nanowire-modified MXene (MXene@AuNWs) nanoplatform to acquire the metabolic fingerprints of urine and serum from XLAS patients and healthy controls. The platform combines the high ionization efficiency of AuNWs with the ordered two-dimensional structure and abundant surface terminations of MXene, enabling the selective enrichment and sensitive detection of small-molecule metabolites; urinary homocysteine and serum phenylalanine hydroxylase (PAH) were quantified by an orthogonal enzyme-linked immunosorbent assay (ELISA).
Results
The platform tolerated high concentrations of salt and protein and was applicable to both urine and serum. The metabolite at m/z 278.43, assigned to urinary homocysteine, was the finding most significantly associated with XLAS (AUC = 0.752), and the ELISA independently confirmed a significantly decreased urinary homocysteine level in patients, whereas serum PAH showed no significant difference between the groups.
Discussion
These results establish MXene@AuNWs-assisted LDI-MS metabolic fingerprinting, cross-validated by immunoassay, as a rapid and label-free route to biomarker discovery in XLAS, and hold substantial potential for future clinical applications.
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Development Foundation
Zitieren
APA
Li, M., Sun, L., Lin, Y., Zhu, S., Zhang, L., Huang, W., & Kuang, X. (2026). Efficient and non-invasive platform for the diagnosis and subtyping of X-linked Alport syndrome leveraging interfacial synergistic engineered MXene@AuNWs. Frontiers in Bioengineering and Biotechnology, 14. https://doi.org/10.3389/fbioe.2026.1958798
Vancouver
Li M, Sun L, Lin Y, Zhu S, Zhang L, Huang W, et al. Efficient and non-invasive platform for the diagnosis and subtyping of X-linked Alport syndrome leveraging interfacial synergistic engineered MXene@AuNWs. Frontiers in Bioengineering and Biotechnology. 2026;14. doi:10.3389/fbioe.2026.1958798
BibTeX
@article{Li2026,
author = {Li, Mengying and Sun, Lei and Lin, Yingqi and Zhu, Siyi and Zhang, Lining and Huang, Wenyan and Kuang, Xinyu},
title = {Efficient and non-invasive platform for the diagnosis and subtyping of X-linked Alport syndrome leveraging interfacial synergistic engineered MXene@AuNWs},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2026},
volume = {14},
doi = {10.3389/fbioe.2026.1958798}
}
EUVIMED